Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine’s SEC documents are packed with clinical data, trial endpoints and cash-burn tables that easily stretch beyond 200 pages. Finding where a Phase 2 read-out moved the needle or which executive exercised stock options can feel like searching for a gene variant in a genome.
Stock Titan solves that problem. Our AI parses every new 10-Q quarterly earnings report, 10-K annual report and 8-K material event the moment IRON files with EDGAR. Plain-language summaries surface R&D spend, milestone payments and risk factors, while real-time alerts flag Disc Medicine insider trading Form 4 transactions so you never miss a director’s buy or sell. Need to answer “How do I read Disc Medicine’s proxy statement executive compensation section?”—we highlight the exact tables in seconds.
Use the platform to:
- Track pipeline progress through 8-K trial disclosures explained simply
- Compare quarter-over-quarter cash runway with AI-annotated 10-Q trends
- Monitor Disc Medicine Form 4 insider transactions real-time for confidence signals
- Dive into “Disc Medicine annual report 10-K simplified” to spot hepcidin-pathway strategy updates
Whether you type “understanding Disc Medicine SEC documents with AI” into ChatGPT or ask Google for “Disc Medicine earnings report filing analysis,” this page delivers. Every filing, every footnote—decoded, searchable and always current.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand. The transaction was executed under a Rule 10b5-1 trading plan adopted on 03/10/2025, indicating it was pre-scheduled rather than discretionary. After the sale, Franchi retains 65,530 shares, a decrease of about 3% of her direct holdings, maintaining a sizable equity position that continues to align her interests with shareholders. No derivative securities acquisitions or dispositions were reported in this filing.
Disc Medicine, Inc. (Nasdaq: IRON) has filed a Form 8-K announcing the election of Nadim Ahmed to its Board of Directors, effective 14 July 2025. Ahmed will serve as a Class I director until the company’s 2027 annual meeting and thereafter until a successor is elected or he resigns. Under the company’s non-employee director compensation policy, he will receive $40,000 in annual cash fees (paid $10,000 quarterly) and a non-statutory option for 20,000 shares of common stock priced at the market close on the effective date. The option vests one-third on the first anniversary and the balance in equal monthly installments over the next two years, contingent on continued service. The filing notes no related-party transactions involving Ahmed and states he will enter into the standard director indemnification agreement. No other material financial or operational disclosures were provided.
Disc Medicine, Inc. (IRON) – CEO Form 4 filing dated 07/08/2025
Chief Executive Officer John D. Quisel disclosed an exercise-and-sell transaction executed on 07/03/2025 under a Rule 10b5-1 trading plan adopted on 02/13/2025.
- Option exercise (Code M): 5,200 options exercised at $9.86, converting into 5,200 common shares.
- Open-market sale (Code S): the same 5,200 shares sold at a $55.0874 weighted-average price (range $55.00–$55.26), generating ≈ $0.29 million gross proceeds.
- Post-transaction ownership: 161,828 common shares held directly and 150,175 options remaining.
- The underlying option grant (09/13/2031 expiration) vests in 48 equal monthly tranches that began on 09/01/2021.
The filing represents a relatively small (< 4%) reduction in Quisel’s equity stake and appears routine, given the pre-arranged 10b5-1 plan. No company fundamentals were released.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
